Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review

Paul E Dato; Jose De La Cerda; Andrew J Armstrong; Arun A Azad; Ciara Conduit; Gabriel P Haas; Kenneth Kernen; Zachary W Klaassen; Raj Patel; Fred Saad; Neal D Shore; Stephen J Freedland; Lawrence I Karsh

doi:10.1080/14796694.2025.2475730

Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review

Future Oncol. 2026 Feb;22(5):605-616. doi: 10.1080/14796694.2025.2475730. Epub 2025 Jun 29.

Authors

Paul E Dato¹, Jose De La Cerda², Andrew J Armstrong³, Arun A Azad^{4

5}, Ciara Conduit^{4

5

6

7}, Gabriel P Haas⁸, Kenneth Kernen⁹, Zachary W Klaassen¹⁰, Raj Patel¹¹, Fred Saad¹², Neal D Shore¹³, Stephen J Freedland^{14

15}, Lawrence I Karsh¹⁶

Affiliations

¹ Genesis Healthcare Partners, San Diego, CA, USA.
² Urology San Antonio, San Antonio, TX, USA.
³ Divisions of Medical Oncology and Urology, Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC, USA.
⁴ Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁵ Medical Oncology, Royal Hobart Hospital, Hobart, Tasmania, Australia.
⁶ The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Sydney, New South Wales, Australia.
⁷ Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
⁸ Global Medical Affairs, Astellas Pharma Inc, Northbrook, IL, USA.
⁹ Michigan Institute of Urology, Troy, MI, USA.
¹⁰ Division of Urology, Medical College of Georgia at Augusta University, Augusta, GA, USA.
¹¹ Formerly of Pfizer Inc., New York, NY, USA.
¹² Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, QC, Canada.
¹³ Carolina Urologic Research Center, Myrtle Beach, SC, USA.
¹⁴ Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Cancer Center, Los Angeles, CA, USA.
¹⁵ The Durham VA Medical Center, Durham, NC, USA.
¹⁶ AdventHealth Urology, Denver, CO, USA.

Abstract

Goal: To present data from published clinical trials of treatment of patients with prostate cancer with enzalutamide described in plain language and in a dashboard format available at: https://clinical-trials.dimensions.ai/enzalutamide-clinical-review/.

Rationale: Treatments that are clinically active in advanced prostate cancer may benefit patients as they are treated earlier in the disease.

Objective: To show how overall survival improves as patients are treated with enzalutamide earlier in the disease.

Keywords: Plain language review; advanced prostate cancer; enzalutamide; metastasis-free survival; overall survival; patient-reported outcomes; prostate cancer; prostate neoplasms.

Publication types

Review

MeSH terms

Antineoplastic Agents* / therapeutic use
Benzamides
Clinical Trials as Topic
Humans
Male
Neoplasm Staging
Nitriles
Phenylthiohydantoin* / administration & dosage
Phenylthiohydantoin* / analogs & derivatives
Phenylthiohydantoin* / therapeutic use
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / mortality
Prostatic Neoplasms* / pathology
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / mortality
Prostatic Neoplasms, Castration-Resistant* / pathology
Treatment Outcome

Substances

enzalutamide
Nitriles
Phenylthiohydantoin
Benzamides
Antineoplastic Agents